Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN)

Historical Holders from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, $0.01 par value
Symbol
VRDN on Nasdaq
Shares outstanding
82,051,282
Price per share
$31.12
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
93,206,726
Total reported value
$2,011,267,220
% of total 13F portfolios
0%
Share change
-1,402,001
Value change
-$24,960,115
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
167
Price from insider filings
$31.16
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Fairmount Funds Management LLC 15% $345,826,621 16,025,330 Fairmount Funds Management LLC 23 Oct 2025
Venrock Healthcare Capital Partners III, L.P. 4.5% $48,373,931 3,575,309 Venrock Healthcare Capital Partners III, L.P. 31 Dec 2024
Commodore Capital LP 3.9% -28% $69,056,000 -$23,738,000 3,200,000 -26% Commodore Capital LP 30 Sep 2025
As of 30 Sep 2025, Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) has 167 institutional shareholders filing 13F forms. They hold 93,206,726 shares .

Top 25 institutional shareholders own 89% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
FMR LLC 15% 12,249,355 +0.09% 0.01% $264,341,081
BlackRock, Inc. 6.6% 5,428,521 -1.7% 0% $117,147,485
Deep Track Capital, LP 6.6% 5,380,449 0% 3.2% $116,110,089
Kynam Capital Management, LP 5.4% 4,427,927 0% 7.1% $95,554,665
VANGUARD GROUP INC 5.3% 4,331,983 -3.9% 0% $93,484,193
VR ADVISER, LLC 4.7% 3,882,709 0% 4.7% $83,788,860
Fairmount Funds Management LLC 4.2% 3,459,913 0% 6.7% $74,664,923
Commodore Capital LP 3.9% 3,200,000 -34% 3.4% $69,056,000
TANG CAPITAL MANAGEMENT LLC 3.5% 2,842,925 0% 2.4% $61,350,322
Paradigm Biocapital Advisors LP 3.2% 2,609,353 -4.8% 1.7% $56,309,838
STATE STREET CORP 3.1% 2,554,166 +0.03% 0% $55,118,902
PRICE T ROWE ASSOCIATES INC /MD/ 2.9% 2,418,104 -16% 0.01% $52,184,000
NOVO HOLDINGS A/S 2.9% 2,380,000 0% 3.3% $51,360,400
MAVERICK CAPITAL LTD 2.7% 2,212,701 -2% 0.64% $47,750,088
Eversept Partners, LP 2.3% 1,924,306 +1.1% 3.2% $41,526,523
ALLIANCEBERNSTEIN L.P. 2.3% 1,859,458 -4.3% 0.01% $40,127,104
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,766,187 +1.5% 0% $38,120,267
BAKER BROS. ADVISORS LP 2.1% 1,744,406 0% 0.27% $37,644,281
LOOMIS SAYLES & CO L P 1.9% 1,550,328 +16% 0.04% $33,456,078
PERCEPTIVE ADVISORS LLC 1.8% 1,462,400 +227% 0.92% $31,558,592
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.5% 1,220,128 +10% 0.04% $26,330,362
Fisher Asset Management, LLC 1.5% 1,201,226 +136% 0.01% $25,922,455
Parkman Healthcare Partners LLC 1.4% 1,154,487 -11% 2.7% $24,913,829
WELLINGTON MANAGEMENT GROUP LLP 1.4% 1,122,532 +315% 0% $24,224,240
Pictet Asset Management Holding SA 1.3% 1,049,385 -17% 0.02% $22,645,728

Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 40,309 $1,254,717 -$692,840 3,111.97% 4
2025 Q3 93,206,726 $2,011,267,220 -$24,960,115 2,158% 167
2025 Q2 94,556,649 $1,321,909,936 +$44,977,645 1,398% 169
2025 Q1 91,362,677 $1,231,598,393 -$2,447,073 1,348% 174
2024 Q4 91,041,740 $1,745,285,274 +$57,671,232 1,917% 177
2024 Q3 86,940,196 $1,978,662,594 +$415,185,793 2,275% 163
2024 Q2 69,645,524 $906,163,827 -$23,346,202 1,301% 137
2024 Q1 71,003,475 $1,243,165,734 +$176,083,012 1,751% 134
2023 Q4 60,143,341 $1,309,923,497 +$204,167,783 2,178% 131
2023 Q3 50,192,424 $769,944,861 +$32,705,128 1,534% 122
2023 Q2 47,119,787 $1,121,040,780 +$92,340,222 2,379% 127
2023 Q1 43,068,809 $1,095,674,908 +$43,441,205 2,544% 134
2022 Q4 41,109,026 $1,200,793,517 +$91,003,851 2,921% 122
2022 Q3 37,976,766 $778,702,810 +$213,427,951 2,051% 104
2022 Q2 28,321,810 $327,687,712 +$27,237,558 1,157.01% 80
2022 Q1 24,929,839 $460,937,688 -$3,304,649 1,848.97% 71
2021 Q4 23,259,955 $459,848,025 +$113,447,608 1,977% 52
2021 Q3 13,600,109 $223,717,000 +$123,512,129 1,644.98% 38
2021 Q2 6,003,456 $109,804,000 +$18,416,912 1,829.03% 24
2021 Q1 5,057,213 $84,503,000 +$80,676,000 1,671% 28
2020 Q4 229,000 $3,767,000 +$3,767,000 1,645.7% 2